X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Religare Enterprises - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs RELIGARE ENT. - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

RELIGARE ENT. 
   Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES RELIGARE ENT. INDOCO REMEDIES/
RELIGARE ENT.
 
P/E (TTM) x 63.8 -4.0 - View Chart
P/BV x 2.3 0.4 629.3% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 INDOCO REMEDIES   RELIGARE ENT.
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
RELIGARE ENT.
Mar-18
INDOCO REMEDIES/
RELIGARE ENT.
5-Yr Chart
Click to enlarge
High Rs360238 151.7%   
Low Rs24934 726.2%   
Sales per share (Unadj.) Rs119.0126.2 94.3%  
Earnings per share (Unadj.) Rs8.4-58.2 -14.4%  
Cash flow per share (Unadj.) Rs15.2-56.3 -27.0%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.782.2 86.0%  
Shares outstanding (eoy) m92.15204.95 45.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.1 237.7%   
Avg P/E ratio x36.4-2.3 -1,559.5%  
P/CF ratio (eoy) x20.0-2.4 -829.4%  
Price / Book Value ratio x4.31.7 260.6%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,08327,863 100.8%   
No. of employees `0006.0NA 17,752.9%   
Total wages/salary Rs m2,1674,984 43.5%   
Avg. sales/employee Rs Th1,817.0760,811.8 0.2%   
Avg. wages/employee Rs Th359.0146,573.5 0.2%   
Avg. net profit/employee Rs Th127.7-350,735.3 -0.0%   
INCOME DATA
Net Sales Rs m10,96825,868 42.4%  
Other income Rs m401,064 3.7%   
Total revenues Rs m11,00726,932 40.9%   
Gross profit Rs m1,565-3,856 -40.6%  
Depreciation Rs m633376 168.3%   
Interest Rs m6212,610 0.5%   
Profit before tax Rs m909-15,779 -5.8%   
Minority Interest Rs m01,579 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m139-2,274 -6.1%   
Profit after tax Rs m771-11,925 -6.5%  
Gross profit margin %14.3-14.9 -95.7%  
Effective tax rate %15.314.4 105.8%   
Net profit margin %7.0-46.1 -15.2%  
BALANCE SHEET DATA
Current assets Rs m5,72576,160 7.5%   
Current liabilities Rs m5,45472,751 7.5%   
Net working cap to sales %2.513.2 18.7%  
Current ratio x1.01.0 100.3%  
Inventory Days Days620 1,102,315.9%  
Debtors Days Days7240 178.6%  
Net fixed assets Rs m5,30715,041 35.3%   
Share capital Rs m1842,050 9.0%   
"Free" reserves Rs m6,33114,797 42.8%   
Net worth Rs m6,51616,846 38.7%   
Long term debt Rs m1,32358,287 2.3%   
Total assets Rs m11,970158,762 7.5%  
Interest coverage x15.6-0.3 -6,226.5%   
Debt to equity ratio x0.23.5 5.9%  
Sales to assets ratio x0.90.2 562.4%   
Return on assets %7.00.4 1,612.1%  
Return on equity %11.8-70.8 -16.7%  
Return on capital %12.4-2.1 -586.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,14112 9,204.8%   
Net fx Rs m3,366-12 -27,141.1%   
CASH FLOW
From Operations Rs m88657,227 1.5%  
From Investments Rs m-1,706-4,220 40.4%  
From Financial Activity Rs m1,316-63,772 -2.1%  
Net Cashflow Rs m497-10,769 -4.6%  

Share Holding

Indian Promoters % 59.2 50.9 116.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.9 1,388.9%  
FIIs % 6.0 15.3 39.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 32.9 68.1%  
Shareholders   12,805 26,518 48.3%  
Pledged promoter(s) holding % 0.0 68.3 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   STC INDIA  TVS SRICHAKRA  ADANI PORTS & SEZ  KOTHARI PRODUCTS  MOTILAL OSWAL  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 139.4% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, INDOCO REMEDIES has posted a net profit of Rs 78 m (down 139.4% YoY). Sales on the other hand came in at Rs 2 bn (down 17.3% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 16, 2018 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS